Freenome, Inc. - Common stock (FRNM)

11.83
+0.68 (6.10%)
NASDAQ· Last Trade: Aug 10th, 12:32 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening –
By Freenome, Inc. · Via GlobeNewswire · July 27, 2026